(GLPG) Galapagos - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: AS (Netherlands) | Market Cap: 1.554m EUR | Total Return: -5.9% in 12m
Avg Turnover: 1.49M
Qual. Beats: 1
Rev. Trend: 90.4%
Qual. Beats: 0
Warnings
Earnings expected to drop: P/E 3.2 → Forward 357.1
Below Avwap Earnings
Tailwinds
No distinct edge detected
Galapagos NV is a biotechnology company developing oncology and immunology treatments. The company operates in the pharmaceutical sector, which is characterized by lengthy and expensive drug development cycles.
Its pipeline includes GLPG3667 (completed Phase 1b) and several CAR-T cell therapies (GLPG5101, GLPG5201, GLPG5301) in Phase 1/2 trials for various blood cancers. CAR-T cell therapy is a complex, personalized medicine business model.
Galapagos has strategic collaboration agreements with Gilead Sciences and AbbVie. Investors might consider reviewing ValueRay for further analysis of GLPGs pipeline and market position.
- Pipeline drug development success drives future revenue
- CAR-T therapy clinical trial results impact valuation
- Collaboration revenue from Gilead and AbbVie is significant
- Regulatory approval timelines affect commercialization
- R&D expenditures are a major cost factor
| Net Income: 488.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -1.16 > 1.0 |
| NWC/Revenue: 283.6% < 20% (prev 1.05k%; Δ -769.6% < -1%) |
| CFO/TA -0.09 > 3% & CFO -292.4m > Net Income 488.8m |
| Net Debt (-2.98b) to EBITDA (634.4m): -4.69 < 3 |
| Current Ratio: 30.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.0m) vs 12m ago 4.82% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 28.23% > 50% (prev 7.17%; Δ 21.07% > 0%) |
| Interest Coverage Ratio: 23.07 > 6 (EBITDA TTM 634.4m / Interest Expense TTM 25.1m) |
| A: 0.88 (Total Current Assets 3.06b - Total Current Liabilities 100.4m) / Total Assets 3.37b |
| B: 0.07 (Retained Earnings 228.3m / Total Assets 3.37b) |
| C: 0.16 (EBIT TTM 578.5m / Avg Total Assets 3.70b) |
| D: 4.34 (Book Value of Equity 516.4m / Total Liabilities 119.1m) |
| Altman-Z'' = 11.58 = AAA |
| DSRI: 0.18 (Receivables 54.0m/83.5m, Revenue 1.04b/288.2m) |
| GMI: 0.86 (GM 98.01% / 84.02%) |
| AQI: 0.64 (AQ_t 0.07 / AQ_t-1 0.11) |
| SGI: 3.62 (Revenue 1.04b / 288.2m) |
| TATA: 0.23 (NI 488.8m - CFO -292.4m) / TA 3.37b) |
| Beneish M = -1.93 (Cap -4..+1) = B |
As of May 24, 2026, the stock is trading at EUR 23.50 with a total of 74,480 shares traded.
Over the past week, the price has changed by +0.59%,
over one month by -3.63%,
over three months by -15.77% and
over the past year by -5.90%.
Galapagos has no consensus analysts rating.
P/E Trailing = 3.1822
P/E Forward = 357.1429
P/S = 1.4887
P/B = 0.4865
Revenue TTM = 1.04b EUR
EBIT TTM = 578.5m EUR
EBITDA TTM = 634.4m EUR
Long Term Debt = 4.85m EUR (estimated: total debt 6.43m - short term 1.58m)
Short Term Debt = 1.58m EUR (from shortTermDebt, last quarter)
Debt = 6.43m EUR (from shortLongTermDebtTotal, last quarter) (leases 6.43m already included)
Net Debt = -2.98b EUR (calculated: Debt 6.43m - CCE 2.98b)
Enterprise Value = 1.55b EUR (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 23.07 (Ebit TTM 578.5m / Interest Expense TTM 25.1m)
EV/FCF = -5.16x (Enterprise Value 1.55b / FCF TTM -301.1m)
FCF Yield = -19.38% (FCF TTM -301.1m / Enterprise Value 1.55b)
FCF Margin = -28.85% (FCF TTM -301.1m / Revenue TTM 1.04b)
Net Margin = 46.83% (Net Income TTM 488.8m / Revenue TTM 1.04b)
Gross Margin = unknown ((Revenue TTM 1.04b - Cost of Revenue TTM 20.8m) / Revenue TTM)
Tobins Q-Ratio = 0.46 (Enterprise Value 1.55b / Total Assets 3.37b)
Interest Expense / Debt = 389.6% (Interest Expense 25.1m / Debt 6.43m)
Taxrate = 0.50% (70.0k / 14.0m)
NOPAT = 575.6m (EBIT 578.5m * (1 - 0.50%))
Current Ratio = 30.48 (Total Current Assets 3.06b / Total Current Liabilities 100.4m)
Debt / Equity = 0.00 (Debt 6.43m / totalStockholderEquity, last quarter 3.25b)
Debt / EBITDA = -4.69 (Net Debt -2.98b / EBITDA 634.4m)
Debt / FCF = 9.88 (negative FCF - burning cash) (Net Debt -2.98b / FCF TTM -301.1m)
Total Stockholder Equity = 3.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.22% (Net Income 488.8m / Total Assets 3.37b)
RoE = 16.28% (Net Income TTM 488.8m / Total Stockholder Equity 3.00b)
RoCE = 19.24% (EBIT 578.5m / Capital Employed (Equity 3.00b + L.T.Debt 4.85m))
RoIC = 24.93% (NOPAT 575.6m / Invested Capital 2.31b)
WACC = 7.08% (E(1.55b)/V(1.56b) * Re(7.11%) + (debt cost/tax rate unavailable))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.52 | Cagr: 2.07%
[DCF] Fair Price = unknown (Cash Flow -301.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.60 | # QB: 1
Revenue Correlation: 90.42 | Revenue CAGR: 115.4% | SUE: -0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.43 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.43 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=-3.05 | Chg30d=+28.24% | Revisions=-43% | GrowthEPS=-129.9% | GrowthRev=-75.5%
EPS next Year (2027-12-31): EPS=-3.91 | Chg30d=+0.00% | Revisions=-33% | GrowthEPS=-28.2% | GrowthRev=-40.3%
[Analyst] Revisions Ratio: -43%